NA Acute Myeloid Leukemia Diagnostics Market - Industry Trends and Forecast to 2035

Description

List of Tables

North America acute myeloid leukemia diagnostics market is projected to register a substantial CAGR of 11.4% in the forecast period of 2024 to 2031. The new market report contains data for the historic year 2022, the base year of calculation is 2023, and the forecast period is 2024 to 2031.

Market Segmentation

North America Acute Myeloid Leukemia Diagnostics Market, By Product Type (Instruments, and Consumables & Accessories), Test Type (Imaging Test, Blood Test, Bone Marrow Test, Biomarker Test, Immunophenotyping, Genetic Testing and Others), Cancer Type (Myeloblastic (M0), Myeloblastic (M1), Myeloblastic (M2), Promyelocytic (M3), Myelomonocytic (M4), MONOCYTIC (M5), Erythroleukemia (M6) and Megakaryocytic (M7)), Age Group (Below 21, 21-29, 30-65, 65 and Above), Gender (Male and Female) End User (Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others), Distribution Channel (Direct Tender and Retail Sales), Country (U.S., Canada, and Mexico) - Industry Trends and Forecast to 2031.

Driver

Increasing diagnostic products for leukemia cancer

Restraint

Late diagnosis and Poor prognosis of leukemia

Opportunity

Initiatives by government and other authorities for life sciences and funding

Market Players

Some of the major market players in North America acute myeloid leukemia diagnostics market are listed below:

F. Hoffmann-La Roche Ltd.
Thermo Fisher Scientific, Inc.
QIAGEN
Abbott
Siemens Healthcare GmbH
Hologic, Inc.
Agilent Technologies, Inc.
DiaSorin S.p.A.
Illumina, Inc.
BIOMERIEUX
Myriad Genetics, Inc.
Quest Diagnostics Incorporated.
Bio-Rad Laboratories, Inc.
Koninklijke Philips N.V.
BD
Exact Sciences Corporation
Time Medical Holding
PlexBio
MinFound Medical Systems Co., Ltd
Medonica Co. LTD
CANON MEDICAL SYSTEMS CORPORATION
Sysmex Corporation
Epigenomics AG
Sonic Healthcare
SternMed GmbH

1 INTRODUCTION 52

1.1 OBJECTIVES OF THE STUDY 52
1.2 MARKET DEFINITION 52
1.3 OVERVIEW OF THE NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET 52
1.4 LIMITATIONS 54
1.5 MARKETS COVERED 55

2 MARKET SEGMENTATION 58

2.1 MARKETS COVERED 58
2.2 GEOGRAPHICAL SCOPE 59
2.3 YEARS CONSIDERED FOR THE STUDY 60
2.4 CURRENCY AND PRICING 60
2.5 DBMR TRIPOD DATA VALIDATION MODEL 61
2.6 MULTIVARIATE MODELLING 64
2.7 PRODUCT TYPE LIFELINE CURVE 64
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 65
2.9 DBMR MARKET POSITION GRID 66
2.10 MARKET END USER COVERAGE GRID 67
2.11 VENDOR SHARE ANALYSIS 68
2.12 SECONDARY SOURCES 69
2.13 ASSUMPTIONS 69

3 EXECUTIVE SUMMARY 70

4 PREMIUM INSIGHTS 73

4.1 PESTEL ANALYSIS 74
4.2 PORTER'S FIVE FORCES 75
4.3 EPIDEMIOLOGY 76

5 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, REGULATIONS 77

5.1 REGULATORY SCENARIO IN THE U.S. 77
5.2 REGULATORY SCENARIO IN AUSTRALIA 78
5.3 REGULATORY SCENARIO IN JAPAN 78
5.4 REGULATORY SCENARIO IN CHINA 78

6 MARKET OVERVIEW 80

6.1 DRIVERS 82
- 6.1.1 GROWING PREVALENCE OF LEUKEMIA CANCER 82
- 6.1.2 NOVEL TECHNOLOGICAL ADVANCEMENTS IN LEUKEMIA DIAGNOSTICS 84
- 6.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 84
- 6.1.4 INCREASE IN AWARENESS REGARDING LEUKEMIA CANCER 85
6.2 RESTRAINTS 85
- 6.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF LEUKEMIA DIAGNOSTIC PRODUCTS 85
- 6.2.2 LATE DIAGNOSIS AND POOR PROGNOSIS OF LEUKEMIA 86
6.3 OPPORTUNITIES 86
- 6.3.1 INCREASE IN DIAGNOSTIC PRODUCTS FOR LEUKEMIA 86
- 6.3.2 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 87
- 6.3.3 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS 88
6.4 CHALLENGES 88
- 6.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES 88
- 6.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 89

7 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE 90

7.1 OVERVIEW 91
7.2 INSTRUMENTS 94
- 7.2.1 BIOPSY INSTRUMENTS 95
  - 7.2.1.1 BONE MARROW BIOPSY 95
  - 7.2.1.2 NEEDLE BIOPSY 95
  - 7.2.1.3 SURGICAL BIOPSY 95
  - 7.2.1.4 OTHERS 95
- 7.2.2 PATHOLOGY-BASED INSTRUMENTS 96
  - 7.2.2.1 PCR INSTRUMENTS 96
  - 7.2.2.2 SLIDE STAINING SYSTEMS 96
  - 7.2.2.3 TISSUE PROCESSING SYSTEMS 96
  - 7.2.2.4 CELL PROCESSORS 96
  - 7.2.2.5 OTHER PATHOLOGY-BASED INSTRUMENTS 96
- 7.2.3 IMAGING INSTRUMENTS 97
  - 7.2.3.1 ULTRASOUND SYSTEMS 97
  - 7.2.3.2 CT SYSTEMS 97
  - 7.2.3.3 MRI SYSTEMS 97
  - 7.2.3.4 OTHERS 97
- 7.2.4 OTHERS 97

7.3 CONSUMABLES & ACCESSORIES 98
- 7.3.1 KITS 99
  - 7.3.1.1 PCR KITS 99
  - 7.3.1.2 DNA POLYMERASE KITS 99
  - 7.3.1.3 NUCLEIC ACID ISOLATION KITS 99
  - 7.3.1.4 OTHERS 99
- 7.3.2 REAGENTS 100
  - 7.3.2.1 ASSAYS 100
  - 7.3.2.2 BUFFERS 100
  - 7.3.2.3 PRIMERS 100
  - 7.3.2.4 OTHERS 100
- 7.3.3 PROBES 101
- 7.3.4 OTHER CONSUMABLES 101

8 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE 102

8.1 OVERVIEW 103
8.2 BLOOD TEST 106
- 8.2.1 COMPLETE BLOOD COUNT (CBC) 107
- 8.2.2 BLOOD CHEMISTRY TESTS 107
- 8.2.3 OTHERS 107
8.3 IMAGING TEST 108
- 8.3.1 COMPUTED TOMOGRAPHY (CT) SCAN 108
- 8.3.2 MRI 108
- 8.3.3 POSITRON EMISSION TOMOGRAPHY (PET) SCAN 109
- 8.3.4 OTHERS 109
8.4 BONE MARROW TESTS 109
- 8.4.1 BONE MARROW ASPIRATE 110
- 8.4.2 BONE MARROW BIOPSY 110
- 8.4.3 OTHERS 110
8.5 GENETIC TESTS 110
- 8.5.1 FLUORESCENCE IN SITU HYBRIDIZATION (FISH) 111
- 8.5.2 KARYOTYPING 111
- 8.5.3 OTHERS 111
8.6 BIOMARKER TEST 112
- 8.6.1 GENETIC ACUTE MYELOID LEUKEMIA (AML) BIOMARKER 112
- 8.6.2 EPIGENETIC ACUTE MYELOID LEUKEMIA (AML) BIOMARKER 112
- 8.6.3 PROTEOMIC ACUTE MYELOID LEUKEMIA (AML) BIOMARKER 113

8.7 IMMUNOPHENOTYPING 113
- 8.7.1 FLOW CYTOMETRY 113
- 8.7.2 IMMUNOHISTOCHEMISTRY 114
- 8.7.3 OTHERS 114
8.8 OTHERS 114

9 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE 115

9.1 OVERVIEW 116
9.2 MYELOBLASTIC (M0) 119
9.3 MYELOBLASTIC (M1) 120
9.4 MYELOBLASTIC (M2) 120
9.5 PROMYELOCYTIC (M3) 121
9.6 MYELOMONOCYTIC (M4) 121
9.7 MONOCYTIC (M5) 122
9.8 ERYTHROLEUKEMIA (M6) 122
9.9 MEGAKARYOCYTIC (M7) 123

10 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP 124

10.1 OVERVIEW 125
10.2 65 AND ABOVE 128
10.3 30-65 129
10.4 BELOW 21 129
10.5 21-29 130

11 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER 131

11.1 OVERVIEW 132
11.2 MALE 135
11.3 FEMALE 136

12 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER 137

12.1 OVERVIEW 138
12.2 HOSPITALS 141
12.3 ASSOCIATED LABS 142
12.4 INDEPENDENT DIAGNOSTIC LABORATORIES 142
12.5 DIAGNOSTIC IMAGING CENTERS 143
12.6 CANCER RESEARCH INSTITUTES 143
12.7 OTHERS 144

13 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 145

13.1 OVERVIEW 146
13.2 DIRECT TENDER 149
13.3 RETAIL SALES 150

14 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION 151

14.1 NORTH AMERICA 154
- 14.1.1 U.S. 160
- 14.1.2 CANADA 165
- 14.1.3 MEXICO 170

15 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: COMPANY LANDSCAPE 175

15.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 175

16 SWOT ANALYSIS 176

17 COMPANY PROFILES 177

17.1 CANON MEDICAL SYSTEMS CORPORATION. 177
- 17.1.1 COMPANY SNAPSHOT 177
- 17.1.2 REVENUE ANALYSIS 178
- 17.1.3 COMPANY SHARE ANALYSIS 178
- 17.1.4 PRODUCT PORTFOLIO 179
- 17.1.5 RECENT DEVELOPMENT 179
17.2 SYSMEX CORPORATION 180
- 17.2.1 COMPANY SNAPSHOT 180
- 17.2.2 REVENUE ANALYSIS 180
- 17.2.3 COMPANY SHARE ANALYSIS 181
- 17.2.4 PRODUCT PORTFOLIO 181
- 17.2.5 RECENT DEVELOPMENT 181
17.3 EPIGENOMICS AG. 182
- 17.3.1 COMPANY SNAPSHOT 182
- 17.3.2 REVENUE ANALYSIS 182
- 17.3.3 COMPANY SHARE ANALYSIS 183
- 17.3.4 PRODUCT PORTFOLIO 183
- 17.3.5 RECENT DEVELOPMENT 184

17.4 MYRIAD GENETICS, INC. 185
- 17.4.1 COMPANY SNAPSHOT 185
- 17.4.2 REVENUE ANALYSIS 185
- 17.4.3 COMPANY SHARE ANALYSIS 186
- 17.4.4 PRODUCT PORTFOLIO 186
- 17.4.5 RECENT DEVELOPMENT 187
17.5 F. HOFFMANN- LA ROCHE LTD 188
- 17.5.1 COMPANY SNAPSHOT 188
- 17.5.2 REVENUE ANALYSIS 188
- 17.5.3 COMPANY SHARE ANALYSIS 189
- 17.5.4 PRODUCT PORTFOLIO 189
- 17.5.5 RECENT DEVELOPMENT 189
17.6 ABBOTT 190
- 17.6.1 COMPANY SNAPSHOT 190
- 17.6.2 REVENUE ANALYSIS 190
- 17.6.3 PRODUCT PORTFOLIO 191
- 17.6.4 RECENT DEVELOPMENT 191
17.7 AGILENT TECHNOLOGIES, INC. 192
- 17.7.1 COMPANY SNAPSHOT 192
- 17.7.2 REVENUE ANALYSIS 192
- 17.7.3 PRODUCT PORTFOLIO 193
- 17.7.4 RECENT DEVELOPMENT 193
17.8 BD 194
- 17.8.1 COMPANY SNAPSHOT 194
- 17.8.2 REVENUE ANALYSIS 194
- 17.8.3 PRODUCT PORTFOLIO 195
- 17.8.4 RECENT DEVELOPMENT 195
17.9 BIOMERIEUX 196
- 17.9.1 COMPANY SNAPSHOT 196
- 17.9.2 PRODUCT PORTFOLIO 196
- 17.9.3 RECENT DEVELOPMENT 196
17.10 BIO-RAD LABORATORIES, INC. 197
- 17.10.1 COMPANY SNAPSHOT 197
- 17.10.2 REVENUE ANALYSIS 197
- 17.10.3 PRODUCT PORTFOLIO 198
- 17.10.4 RECENT DEVELOPMENT 198

17.11 DIASORIN S.P.A. 199
- 17.11.1 COMPANY SNAPSHOT 199
- 17.11.2 REVENUE ANALYSIS 199
- 17.11.3 PRODUCT PORTFOLIO 200
- 17.11.4 RECENT DEVELOPMENTS 200
17.12 EXACT SCIENCES CORPORATION 201
- 17.12.1 COMPANY SNAPSHOT 201
- 17.12.2 REVENUE ANALYSIS 201
- 17.12.3 PRODUCT PORTFOLIO 202
- 17.12.4 RECENT DEVELOPMENTS 202
17.13 HOLOGIC INC. 203
- 17.13.1 COMPANY SNAPSHOT 203
- 17.13.2 REVENUE ANALYSIS 203
- 17.13.3 PRODUCT PORTFOLIO 204
- 17.13.4 RECENT DEVELOPMENT 204
17.14 ILLUMINA, INC. 205
- 17.14.1 COMPANY SNAPSHOT 205
- 17.14.2 REVENUE ANALYSIS 205
- 17.14.3 PRODUCT PORTFOLIO 206
- 17.14.4 RECENT DEVELOPMENT 206
17.15 KONINKLIJKE PHILIPS N.V. 207
- 17.15.1 COMPANY SNAPSHOT 207
- 17.15.2 REVENUE ANALYSIS 207
- 17.15.3 PRODUCT PORTFOLIO 208
- 17.15.4 RECENT DEVELOPMENT 208
17.16 MEDONICA CO. LTD 209
- 17.16.1 COMPANY SNAPSHOT 209
- 17.16.2 PRODUCT PORTFOLIO 209
- 17.16.3 RECENT DEVELOPMENT 209
17.17 MINFOUND MEDICAL SYSTEMS CO., LTD 210
- 17.17.1 COMPANY SNAPSHOT 210
- 17.17.2 PRODUCT PORTFOLIO 210
- 17.17.3 RECENT DEVELOPMENT 211
17.18 PLEXBIO 212
- 17.18.1 COMPANY SNAPSHOT 212
- 17.18.2 PRODUCT PORTFOLIO 212
- 17.18.3 RECENT DEVELOPMENTS 212

17.19 QIAGEN 213
- 17.19.1 COMPANY SNAPSHOT 213
- 17.19.2 REVENUE ANALYSIS 213
- 17.19.3 PRODUCT PORTFOLIO 214
- 17.19.4 RECENT DEVELOPMENTS 214
17.20 QUEST DIAGNOSTICS INCORPORATED 215
- 17.20.1 COMPANY SNAPSHOT 215
- 17.20.2 REVENUE ANALYSIS 215
- 17.20.3 PRODUCT PORTFOLIO 216
- 17.20.4 RECENT DEVELOPMENTS 216
17.21 SIEMENS HEALTHCARE GMBH 217
- 17.21.1 COMPANY SNAPSHOT 217
- 17.21.2 REVENUE ANALYSIS 217
- 17.21.3 PRODUCT PORTFOLIO 218
- 17.21.4 RECENT DEVELOPMENT 218
17.22 SONIC HEALTHCARE 219
- 17.22.1 COMPANY SNAPSHOT 219
- 17.22.2 PRODUCT PORTFOLIO 219
- 17.22.3 RECENT DEVELOPMENT 219
17.23 STERNMED GMBH 220
- 17.23.1 COMPANY SNAPSHOT 220
- 17.23.2 PRODUCT PORTFOLIO 220
- 17.23.3 RECENT DEVELOPMENTS 220
17.24 THERMO FISHER SCIENTIFIC INC. 221
- 17.24.1 COMPANY SNAPSHOT 221
- 17.24.2 REVENUE ANALYSIS 221
- 17.24.3 PRODUCT PORTFOLIO 222
- 17.24.4 RECENT DEVELOPMENT 222
17.25 TIME MEDICAL HOLDING 223
- 17.25.1 COMPANY SNAPSHOT 223
- 17.25.2 PRODUCT PORTFOLIO 223
- 17.25.3 RECENT DEVELOPMENT 224

18 QUESTIONNAIRE 225

19 RELATED REPORTS 229

LIST OF TABLES

TABLE 1 APPROVED DIAGNOSTICS OF LEUKEMIA 56
TABLE 2 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 63
TABLE 3 NORTH AMERICA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 63
TABLE 4 NORTH AMERICA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 63
TABLE 5 NORTH AMERICA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 64
TABLE 6 NORTH AMERICA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 65
TABLE 7 NORTH AMERICA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 66
TABLE 8 NORTH AMERICA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 67
TABLE 9 NORTH AMERICA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 67
TABLE 10 NORTH AMERICA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 68
TABLE 11 NORTH AMERICA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 69
TABLE 12 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 75
TABLE 13 NORTH AMERICA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 75
TABLE 14 NORTH AMERICA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 76
TABLE 15 NORTH AMERICA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 77
TABLE 16 NORTH AMERICA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 77
TABLE 17 NORTH AMERICA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 78
TABLE 18 NORTH AMERICA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 78
TABLE 19 NORTH AMERICA GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 79
TABLE 20 NORTH AMERICA GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 80
TABLE 21 NORTH AMERICA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 81
TABLE 22 NORTH AMERICA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 81
TABLE 23 NORTH AMERICA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 82
TABLE 24 NORTH AMERICA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 82
TABLE 25 NORTH AMERICA OTHERS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 83
TABLE 26 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION) 88
TABLE 27 NORTH AMERICA MYELOBLASTIC (M0) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 88
TABLE 28 NORTH AMERICA MYELOBLASTIC (M1) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 89
TABLE 29 NORTH AMERICA MYELOBLASTIC (M2) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 89
TABLE 30 NORTH AMERICA PROMYELOCYTIC (M3) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 90
TABLE 31 NORTH AMERICA MYELOMONOCYTIC (M4) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 90
TABLE 32 NORTH AMERICA MONOCYTIC (M5) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 91
TABLE 33 NORTH AMERICA ERYTHROLEUKEMIA (M6) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 91
TABLE 34 NORTH AMERICA MEGAKARYOCYTIC (M7) ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 92
TABLE 35 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION) 97
TABLE 36 NORTH AMERICA 65 AND ABOVE IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 97
TABLE 37 NORTH AMERICA 30-65 IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 98
TABLE 38 NORTH AMERICA BELOW 21 IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 98
TABLE 39 NORTH AMERICA 21-29 IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 99
TABLE 40 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION) 104
TABLE 41 NORTH AMERICA MALE IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 104
TABLE 42 NORTH AMERICA FEMALE IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 105
TABLE 43 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION) 110
TABLE 44 NORTH AMERICA HOSPITALS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 110
TABLE 45 NORTH AMERICA ASSOCIATED LABS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 111
TABLE 46 NORTH AMERICA INDEPENDENT DIAGNOSTIC LABORATORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 111
TABLE 47 NORTH AMERICA DIAGNOSTIC IMAGING CENTERS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 112
TABLE 48 NORTH AMERICA CANCER RESEARCH INSTITUTES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 112
TABLE 49 NORTH AMERICA OTHERS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 113
TABLE 50 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 118
TABLE 51 NORTH AMERICA DIRECT TENDER IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 118
TABLE 52 NORTH AMERICA RETAIL SALES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION) 119
TABLE 53 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY COUNTRY, 2022-2031 (USD MILLION) 123
TABLE 54 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 123
TABLE 55 NORTH AMERICA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 123
TABLE 56 NORTH AMERICA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 123
TABLE 57 NORTH AMERICA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 124
TABLE 58 NORTH AMERICA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 124
TABLE 59 NORTH AMERICA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 124
TABLE 60 NORTH AMERICA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 124
TABLE 61 NORTH AMERICA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 125
TABLE 62 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 125
TABLE 63 NORTH AMERICA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 125
TABLE 64 NORTH AMERICA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 125
TABLE 65 NORTH AMERICA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 126
TABLE 66 NORTH AMERICA GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 126
TABLE 67 NORTH AMERICA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 126
TABLE 68 NORTH AMERICA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 126
TABLE 69 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION) 127
TABLE 70 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION) 127
TABLE 71 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION) 127
TABLE 72 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION) 127
TABLE 73 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 128
TABLE 74 U.S. ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 129
TABLE 75 U.S. INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 129
TABLE 76 U.S. BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 129
TABLE 77 U.S. PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 129
TABLE 78 U.S. IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 130
TABLE 79 U.S. CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 130
TABLE 80 U.S. KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 130
TABLE 81 U.S. REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 130
TABLE 82 U.S. ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 131
TABLE 83 U.S. BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 131
TABLE 84 U.S. IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 131
TABLE 85 U.S. BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 131
TABLE 86 U.S. GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 132
TABLE 87 U.S. BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 132
TABLE 88 U.S. IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 132
TABLE 89 U.S. ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION) 132
TABLE 90 U.S. ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION) 133
TABLE 91 U.S. ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION) 133
TABLE 92 U.S. ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION) 133
TABLE 93 U.S. ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 133
TABLE 94 CANADA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 134
TABLE 95 CANADA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 134
TABLE 96 CANADA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 134
TABLE 97 CANADA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 134
TABLE 98 CANADA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 135
TABLE 99 CANADA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 135
TABLE 100 CANADA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 135
TABLE 101 CANADA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 135
TABLE 102 CANADA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 136
TABLE 103 CANADA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 136
TABLE 104 CANADA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 136
TABLE 105 CANADA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 136
TABLE 106 CANADA GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 137
TABLE 107 CANADA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 137
TABLE 108 CANADA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 137
TABLE 109 CANADA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION) 137
TABLE 110 CANADA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION) 138
TABLE 111 CANADA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION) 138
TABLE 112 CANADA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION) 138
TABLE 113 CANADA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 138
TABLE 114 MEXICO ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 139
TABLE 115 MEXICO INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 139
TABLE 116 MEXICO BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 139
TABLE 117 MEXICO PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 139
TABLE 118 MEXICO IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 140
TABLE 119 MEXICO CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 140
TABLE 120 MEXICO KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 140
TABLE 121 MEXICO REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 140
TABLE 122 MEXICO ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 141
TABLE 123 MEXICO BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 141
TABLE 124 MEXICO IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 141
TABLE 125 MEXICO BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 141
TABLE 126 MEXICO GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 142
TABLE 127 MEXICO BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 142
TABLE 128 MEXICO IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION) 142
TABLE 129 MEXICO ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION) 142
TABLE 130 MEXICO ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION) 143
TABLE 131 MEXICO ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION) 143
TABLE 132 MEXICO ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION) 143
TABLE 133 MEXICO ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 143

LIST OF FIGURES

FIGURE 1 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: SEGMENTATION 27
FIGURE 2 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: DATA TRIANGULATION 30
FIGURE 3 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: DROC ANALYSIS 31
FIGURE 4 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS 32
FIGURE 5 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS 32
FIGURE 6 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS 34
FIGURE 7 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : DBMR MARKET POSITION GRID 35
FIGURE 8 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: MARKET END USER COVERAGE GRID 36
FIGURE 9 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS 37
FIGURE 10 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: SEGMENTATION 41
FIGURE 11 THE GROWING PREVALENCE OF LEUKEMIA CANCER IS EXPECTED TO DRIVE THE NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET IN THE FORECAST PERIOD 42
FIGURE 12 THE INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET IN 2024 & 2031 42
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET 50
FIGURE 14 NUMBER OF PREVALENCE OF LEUKEMIA INCIDENCE WORLDWIDE (BOTH SEXES) 52
FIGURE 15 FIVE YEARS PREVALENCE LEUKEMIA INCIDENCE WORLDWIDE (BOTH SEXES) 52
FIGURE 16 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2023 60
FIGURE 17 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2024-2031 (USD MILLION) 61
FIGURE 18 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2024-2031) 61
FIGURE 19 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE 62
FIGURE 20 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY TEST TYPE, 2023 72
FIGURE 21 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY TEST TYPE, 2024-2031 (USD MILLION) 73
FIGURE 22 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2024-2031) 73
FIGURE 23 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE 74
FIGURE 24 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY CANCER TYPE, 2023 85
FIGURE 25 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY CANCER TYPE, 2024-2031 (USD MILLION) 86
FIGURE 26 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY CANCER TYPE, CAGR (2024-2031) 86
FIGURE 27 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY CANCER TYPE, LIFELINE CURVE 87
FIGURE 28 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY AGE GROUP, 2023 94
FIGURE 29 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY AGE GROUP, 2024-2031 (USD MILLION) 95
FIGURE 30 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY AGE GROUP, CAGR (2024-2031) 95
FIGURE 31 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY AGE GROUP, LIFELINE CURVE 96
FIGURE 32 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY GENDER, 2023 101
FIGURE 33 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY GENDER, 2024-2031 (USD MILLION) 102
FIGURE 34 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY GENDER, CAGR (2024-2031) 102
FIGURE 35 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY GENDER, LIFELINE CURVE 103
FIGURE 36 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY END USER, 2023 107
FIGURE 37 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY END USER, 2024-2031 (USD MILLION) 108
FIGURE 38 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY END USER, CAGR (2024-2031) 108
FIGURE 39 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE 109
FIGURE 40 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023 115
FIGURE 41 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION) 116
FIGURE 42 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031) 116
FIGURE 43 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 117
FIGURE 44 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: SNAPSHOT (2023) 121
FIGURE 45 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: COMPANY SHARE 2023(%) 144